Related Experiment Video

Updated: Jun 23, 2026

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomas

Avaniyapuram Kannan Murugan, Jianli Dong, Jingwu Xie

    Cell Cycle (Georgetown, Tex.)
    |May 5, 2009
    PubMed

    Insights

    Researchers investigated MEK1 and ERK2 mutations in melanoma, colon, and thyroid cancers. Activating MEK1 mutations were found at low prevalence in melanoma and colon cancer, offering potential therapeutic targets.

    Area of Science:

    • Oncology
    • Molecular Biology
    • Cancer Genetics

    Background:

    • The Mitogen-activated protein kinase (MAPK) signaling pathway is crucial in melanoma, colon, and thyroid cancer pathogenesis, often involving RAS and BRAF mutations.
    • Mutations in MEK1 exon 2 and ERK2 exon 7 are less studied in these cancers despite their occurrence elsewhere.

    Discussion:

    • This study analyzed 185 samples (167 tumors, 18 cell lines) of melanoma, colon, and thyroid cancer for MEK1 and ERK2 mutations.
    • MEK1 mutations were identified in 3% of melanoma and 2.2% of colon cancer samples, but not in thyroid cancer.
    • No ERK2 mutations were detected in any of the analyzed samples.

    Key Insights:

    • This research reports the first identification of MEK1 mutations in melanoma and colon cancer, revealing a low prevalence.
    • The identified MEK1 mutants are activating, suggesting their role in cancer progression.
    • These findings highlight MEK1 as a potential therapeutic target for specific melanoma and colon cancer cases.

    Outlook:

    • Further research is needed to fully elucidate the role of MEK1 mutations in cancer.
    • Exploring the therapeutic efficacy of targeting MEK1 in relevant patient populations is warranted.
    • Investigating MEK1 and ERK2 mutations in a broader range of cancer types may reveal additional insights.

    More Related Videos

    A 3D Organotypic Melanoma Spheroid Skin Model08:49

    A 3D Organotypic Melanoma Spheroid Skin Model

    Published on: May 18, 2018

    Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer08:34

    Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer

    Published on: April 13, 2015

    Related Concept Videos

    Mitogens and the Cell Cycle02:38

    Mitogens and the Cell Cycle

    Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
    Cancers Originate from Somatic Mutations in a Single Cell02:21

    Cancers Originate from Somatic Mutations in a Single Cell

    Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
    Cancers Originate from Somatic Mutations in a Single Cell02:21

    Cancers Originate from Somatic Mutations in a Single Cell

    Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
    Mismatch Repair01:20

    Mismatch Repair

    Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
    The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
    The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
    Mismatch Repair01:36

    Mismatch Repair

    Overview
    The Ras Gene02:38

    The Ras Gene

    The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
    Ras is a superfamily...